Defining the Appropriate Patient Population for Primary Brachytherapy for Localized Prostate Cancer: Work in Progress

Frank, Igor; Blute, Michael L.
March 2004
Mayo Clinic Proceedings;Mar2004, Vol. 79 Issue 3, p307
Academic Journal
Industry Overview
No single treatment modality for localized prostate cancer is ideal for every patient. As the number of treatment options expands, the need for evidence-based stratification tools increases. Such data-based tools would enable the clinician and patient to identify treatment choices associated with the least morbidity, without altering rates of disease control, on the basis of the patient's individual anatomical and physiological characteristics. Treatment-related morbidity has been a subject of much research in recent years and has become a major comparison point for treatment selection.


Related Articles

  • Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. Langsenlehner, Tanja; Thurner, Eva-Maria; Krenn-Pilko, Sabine; Langsenlehner, Uwe; Stojakovic, Tatjana; Gerger, Armin; Pichler, Martin // World Journal of Urology;Nov2015, Vol. 33 Issue 11, p1661 

    Purpose: Recent studies have expanded the concept that the systemic inflammatory response has an important role in the progression of several solid tumors. The neutrophil-to-lymphocyte ratio (NLR), an easily determinable marker of systemic inflammation, has been associated with clinical outcome...

  • Focal Therapy for Prostate Cancer. Emberton, Mark; Konijeti, Ramdev; Kibel, Adam S. // AUANews;Sep2012, Vol. 17 Issue 9, p19 

    The article presents a debate about focal therapy for prostate cancer. A physician says focal therapy should be seen as a legitimate, necessary response to a changing diagnostic and therapeutic pathway for prostate cancer. However, two physicians noted that the multifocal nature of prostate...

  • Reflections on the EAU Annual Congress. Charnow, Jody A. // Renal & Urology News;Apr2013, Vol. 12 Issue 4, p6 

    The author offers views about the European Association of Urology Annual Conference which presented several studies of the treatment of localized prostate cancer (PCa).

  • New National Air-Kerma-Strength Standards For 125I and 103Pd Brachytherapy Seeds. Seltzer, Stephen M.; Lamperti, Paul J.; Loevinger, Robert; Mitch, Michael G.; Weaver, James T.; Coursey, Bert M. // Journal of Research of the National Institute of Standards & Tec;Sep/Oct2003, Vol. 108 Issue 5, p337 

    The new U.S. measurement standard for the air-kerma strength from low-energy photon-emitting brachytherapy seed sources is formally described in detail. This instrument-based standard was implemented on 1 January 1999, with its salient features and the implications of differences with the...

  • Is Bilateral Orchiectomy for Metastatic Prostate Cancer Treatment Associated with High Cardiovascular Risk? Stamatiou, Konstantinos; Stamatopoulou, Eleni; Christopoulos, George // Aging & Disease;Dec2013, Vol. 4 Issue 6, p381 

    Cardiovascular disease is one of the most common causes of death worldwide and the most usual in the western populations. Although it affects both sexes, it is more frequent in males in whom it shortens the average life expectancy. This difference has been attributed to the negative effects of...

  • Potential risk of alpha-glucosidase inhibitor administration in prostate cancer external radiotherapy by exceptional rectal gas production: a case report. Takuya Nishimura; Hideya Yamazaki; Kazuki Iwama; Yoshitaka Oota; Norihiro Aibe; Satoaki Nakamura; Ken Yoshida; Haruumi Okabe; Kei Yamada // Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p1 

    Introduction Radiotherapy is a standard treatment for prostate cancer, and image-guided radiotherapy is increasingly being used to aid precision of dose delivery to targeted tissues. However, precision during radiotherapy cannot be maintained when unexpected intrafraction organ motion occurs....

  • Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue. Gillard, Marc; Tom, Westin R.; Antic, Tatjana; Paner, Gladell P.; Lingen, Mark W.; VanderWeele, David J. // American Journal of Translational Research;2015, Vol. 7 Issue 7, p1227 

    Background: Personalization of cancer therapy requires molecular evaluation of tumor tissue. Traditional tissue preservation involves formalin fixation, which degrades the quality of nucleic acids. Strategies to bank frozen prostate tissue can interfere with diagnostic studies. PAXgene is an...

  • Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses. Höti, N.; Chowdhury, W. H.; Mustafa, S.; Ribas, J.; Castanares, M.; Johnson, T.; Liu, M.; Lupold, S. E.; Rodriguez, R. // Cancer Gene Therapy;Aug2010, Vol. 17 Issue 8, p585 

    Conditionally replicating adenoviruses (CRAds) represent a promising modality for the treatment of neoplastic diseases, including Prostate Cancer. Selectively replicating viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required...

  • Robotic-assisted laparoscopic prostatectomy. Sharma, N. L.; Shah, N. C.; Neal, D. E. // British Journal of Cancer;11/3/2009, Vol. 101 Issue 9, p1491 

    Prostate cancer remains a significant health problem worldwide and is the second highest cause of cancer-related death in men. While there is uncertainty over which men will benefit from radical treatment, considerable efforts are being made to reduce treatment related side-effects and in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics